Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 2;40(4):1937–1946. doi: 10.3892/or.2018.6625

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — CAPN2 is upregulated in gefitinib-resistant cells and mediates gefitinib resistance. (A) CAPN2 mRNA expression was measured by reverse transcription-quantitative polymerase chain reaction in gefitinib-sensitive and gefitinib-resistant NSCLC cell lines. (B) Representative western blots highlighting CAPN2 protein expression and (C) changes in CAPN2 protein levels quantified by scanning densitometry in gefitinib-sensitive and gefitinib-resistant NSCLC cell lines. (D) Cytotoxic effects of gefitinib on PC9, PC9R, HCC4006 and HCC4006R cells measured by cell counting kit-8 (n=4). *P<0.05 vs. the corresponding gefitinib-sensitive cells. (E) CAPN2 mRNA expression following transfection of PC9R and HCC4006R cells with shNEG, or with shCAPN2-1 and shCAPN2-2 to silence CAPN2 expression. (F) Representative immunoblots and (G) scanning densitometry-quantified levels of CAPN2 protein expression following shRNA transfection. Morphological examination of shRNA-transfected (H) PC9R and (I) HCC4006R cells, indicating that CAPN2 knockdown reduces the number of resistant cells in gefitinib-resistant cultures. Cytotoxic effects of gefitinib on shRNA-transfected (J) PC9R and (K) HCC4006R cells (n=4). *P<0.05 vs. shNEG group. CAPN2, calpain 2; NSCLC, non-small cell lung cancer; shRNA, short hairpin RNA; shNEG, negative control shRNA; shCAPN2, CAPN2 shRNA.